Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome

Mendelian MONDO:0013618 Pathograph 12 Show in embeddings browser Anterior segment dysgenesis Hereditary disease

CAASDS (OMIM 614195) rests on a single publication: one three-generation African American family, four affected members, reported in 2004. A PubMed search on 2026-09-08 for the syndrome name, and for VSX1 with craniofacial or anterior segment terms, returned no second family in the twenty-two years since. This entry is therefore as much about the limits of the evidence as about the disease, and it is written that way rather than presenting a four-person phenotype as an established entity. What the family shows is consistent. Craniofacial features - wide interpupillary distance and unusual pinnae - were present in all four affected members, and anterior segment anomalies of the corneal endothelium were described as a constant finding in all of them. Beyond that the expressivity is extreme: the proband had an empty sella turcica, a posterior fossa cyst, an anterior encephalocele and severe hydrocephalus, her mother had a partially empty sella with a small pituitary and hypertelorism, and her older sister had hypertelorism and otherwise normal neuroimaging. Electrophysiology found abnormal cone bipolar cell function in the affected adults and abnormal auditory bipolar cell function in the proband. Two VSX1 changes segregate with the phenotype, and they sit on the same chromosome: R131S, which the authors classify as a variation outside a critical region and present in a few controls, and A256S, in the conserved CVC domain and absent from controls. Only the second is offered as the mutation. That matters, because R131S is catalogued elsewhere as a previously reported single-nucleotide polymorphism, found in a keratoconus cohort in which no VSX1 variant proved pathogenic. The gene's disease associations are contested more broadly, and this entry carries that context because it bears directly on how much weight the entity can take. VSX1 was originally reported for posterior polymorphous corneal dystrophy and keratoconus; dismech already records those assignments as unconfirmed or of uncertain significance in Posterior_Polymorphous_Corneal_Dystrophy, and types VSX1 as DISPUTED in Keratoconus. A mouse carrying the equivalent of the VSX1 CVC-domain change p.P247R has no corneal defect at all, though it does have an abnormal electroretinogram, and the authors of that study conclude that VSX1 on its own does not appear to play a major causative role in corneal disease. There is no ClinGen gene-disease validity assertion for VSX1. The one part of this phenotype with independent mechanistic support is the retinal electrophysiology. VSX1 is a paired-like homeodomain transcriptional repressor expressed in retinal bipolar cells; it regulates terminal differentiation of type 7 ON bipolar cells in mouse, and abnormal inner-retinal function on electroretinography has been reported in carriers of two other VSX1 changes in an unrelated family. The craniofacial and sellar findings have no proposed mechanism in any source read here, and none is invented.

Ask OpenScientist

Ask a research question about Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
7
Phenotypes
2
Gaps
12
Pathograph
1
Genes
6
References
1
Deep Research
🏷

Classifications

Harrison's Part
GENETICS ENVIRONMENT DISEASE OTHER
👪

Inheritance

1
Autosomal dominant inheritance HP:0000006
The two VSX1 changes were present on one chromosome at 20p11.2 and segregated with the four affected members of a three-generation pedigree, which is a dominant pattern in a single family. Nothing stronger can be said: there is no second family, no de novo event, and no functional demonstration that either change is pathogenic. Expressivity within the family is described by the authors as extremely variable, so the pattern is segregation in one pedigree rather than an established mode of inheritance.
Autosomal dominant inheritance
Show evidence (2 references)
PMID:15051220 SUPPORT Human Clinical
"Both were present on 1 chromosome at 20p11.2 and were segregated with the 4 affected patients."
The segregation evidence, and the fact that the two changes travel together on one chromosome rather than as independent alleles.
PMID:15051220 SUPPORT Human Clinical
"Clinical features demonstrated extremely variable expressivity."
The authors' own summary of how differently the same genotype presented within one family, which is what makes any frequency claim from this series fragile.
?

Discussions and Knowledge Gaps

2
Is CAASDS a distinct disease entity, or a single family's coincidence around a VSX1 polymorphism?
OPEN QUESTION OPEN caasds_is_this_a_real_entity
Attached to
disease# genetic#VSX1
The question has to be asked because everything that would normally answer it is missing. One family, four affected members, one paper, 2004, and nothing since - a PubMed search on 2026-09-08 for the syndrome name and for VSX1 with craniofacial, anterior segment and sella terms returned no second family. The genotype is two coding changes in cis, and the reporting authors classify one of them, R131S, as a variation rather than a mutation; it turns up elsewhere as a previously reported polymorphism in a keratoconus cohort. The other, A256S, sits in the conserved CVC domain and was absent from controls, which is suggestive and is not a functional result - the change has never been assayed. Three things argue the entity is real, and they should not be dismissed. The craniofacial features and the corneal endothelial anomalies were present in all four affected members and absent from the unaffected ones, which is what segregation looks like. The retinal electrophysiology has independent support from two directions: Vsx1 controls terminal gene expression in mouse type 7 ON bipolar cells, and a mouse carrying a VSX1 CVC-domain change has an abnormal electroretinogram. And OMIM and MONDO both carry the entity, so it is at least a concept other resources have accepted. Three argue the other way. VSX1's better-studied disease associations have weakened rather than strengthened - dismech already records the PPCD1 assignment as unconfirmed and types the gene DISPUTED in keratoconus. The same mouse that reproduces the retinal finding has no corneal defect, and its authors conclude VSX1 does not on its own play a major causative role in corneal disease. And the craniofacial and sellar half of the phenotype, which is what the syndrome is named for, has no proposed mechanism, no animal correlate and no second observation anywhere. The honest position, and the one this entry takes, is that the entity is curated because it exists as a named concept with a real published pedigree behind it, and that every causal claim in it is marked at the strength the source supports rather than at the strength the disease name implies. What would settle it is a second family, or a functional assay of A256S. Neither has been done.
Proposed experiments
Assay A256S repressor activity against the tested VSX1 missense panel
exp_caasds_a256s_repressor_assay
The published luciferase reporter assay for VSX1 transcriptional repression has already been run against a panel of VSX1 missense changes, including the CVC-domain change P247R. Running A256S through the same assay alongside that panel would say whether the one change this entity rests on does anything to repressor function, and in which direction. A result matching P247R - enhanced repression - would be as informative as a loss, because it would mean the entity's causal account has to be rewritten rather than confirmed.
Readouts
VSX1 transcriptional repressor activity for A256S relative to wild type
pathophysiology#Impaired VSX1 Transcriptional Repression
Direction: ALTERED
Interpretation: Any reproducible difference from wild type would move this node off PROVISIONAL; no difference would argue that A256S is not the causal change either.
Would support
pathophysiology#Impaired VSX1 Transcriptional Repression
Supporting outcome
  • Reduced repressor activity for A256S would support the causal chain this entry draws; unchanged or enhanced activity would leave the entity without a molecular mechanism.
Show evidence (3 references)
PMID:15051220 SUPPORT Human Clinical
"Two changes in VSX1 (RINX) were identified: a variation (R131S) not in a critical region and in few controls, and a mutation (A256S) in the critical CVC-domain and not in any controls."
The genotype at the centre of the question, with the authors' own asymmetric classification of its two halves.
PMID:16799019 REFUTE Human Clinical
"Two previously reported SNPs were also identified: c.426C>A (Arg131Ser) in one affected patient and c.581A>G (Ala182Ala) in 51 of the 100 affected patients."
That one of the two changes is a circulating polymorphism, which removes it from the causal account and leaves the entity resting on a single untested substitution.
PMID:30535423 REFUTE Model Organism
"A mouse model for VSX1 p.P247R did not have any observable corneal defect, but did exhibit an abnormal electroretinogram response characterized by a more prominent ON as opposed to OFF panretinal responsiveness."
The experiment that splits this phenotype - the retinal half reproduces in a model, the corneal half does not.
Is there anything to curate about management?
KNOWLEDGE GAP OPEN caasds_no_treatment_or_natural_history
Attached to
treatments#
No. The source is a genotype-phenotype study, not a clinical follow-up, and it reports no intervention for any family member - not for the severe hydrocephalus in the proband, which would certainly have been managed somehow, and not for the corneal, retinal or auditory findings. No treatment, no outcome and no natural history is recoverable from it, and there is no second report to supply them. Generic management of the individual findings - shunting for hydrocephalus, corneal transplantation for endothelial failure, hearing amplification - would look plausible in a treatments block and would be an invention. None of it is reported of these patients, and importing it would assert of four people an experience recorded only of others. The treatments section is therefore empty, deliberately, and this discussion is why.
Show evidence (1 reference)
PMID:15051220 NO_EVIDENCE Human Clinical
"Main outcome measures included identification and molecular characterization of 1 variation and 1 mutation in VSX1 (RINX) of 4 affected family members (3 adults and 1 child)."
The study's stated outcome measures are molecular and descriptive. Recorded as NO_EVIDENCE because the source does not bear on treatment at all, rather than bearing on it negatively.
⚙

Pathophysiology

5
VSX1 CVC-Domain Substitution in cis with a Coding Variant
Two changes in VSX1, on the same chromosome, in all four affected members. R131S lies outside a critical region and was found in a few controls, and the authors class it as a variation rather than a mutation; A256S falls in the conserved CVC domain and was found in no control. Only A256S is offered as the causal change. The distinction is not academic: R131S is independently catalogued as a previously reported single-nucleotide polymorphism in a keratoconus cohort in which no VSX1 variant proved pathogenic.
VSX1 hgnc:12723 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves VSX1 (hgnc:12723). hgnc:12723 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context VSX1 hgnc:12723 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns VSX1 (hgnc:12723). hgnc:12723 is a gene from the HUGO Gene Nomenclature Committee. allele_type: two coding substitutions in cis, R131S and A256S, the latter in the CVC domain variant_origin: GERMLINE zygosity: HETEROZYGOUS
Heterozygous in all four affected members of one pedigree, both changes on the same chromosome. No second family has been reported.
No functional_impact_category is recorded, and that is deliberate. Neither change has been functionally characterised. The published in vitro work on VSX1 covers the homeodomain change R166W, which impairs DNA binding and hinders repressor function, and a set of missense changes that either enhanced repressor activity or left it unaltered - A256S is not among them. Assigning LOSS_OF_FUNCTION or GAIN_OF_FUNCTION here would be an inference from domain position rather than a measurement, and the direction is not even predictable: the closest characterised CVC-domain change, P247R, enhanced rather than reduced repressor activity.
Downstream
Impaired VSX1 Transcriptional Repression
Show evidence (2 references)
PMID:15051220 SUPPORT Human Clinical
"Two changes in VSX1 (RINX) were identified: a variation (R131S) not in a critical region and in few controls, and a mutation (A256S) in the critical CVC-domain and not in any controls."
Both changes with the authors' own classification of each, which is the reason this entry treats only one of the two as a candidate cause.
PMID:16799019 SUPPORT INDIRECT Human Clinical
"Two previously reported SNPs were also identified: c.426C>A (Arg131Ser) in one affected patient and c.581A>G (Ala182Ala) in 51 of the 100 affected patients."
Independent evidence that R131S circulates as a polymorphism. INDIRECT because the cohort is a keratoconus series rather than this syndrome, but it is the same nucleotide change and it bears directly on how much of this genotype can be doing any work.
Impaired VSX1 Transcriptional Repression
Mechanism confidence: Provisional
VSX1 is a paired-like homeodomain protein that acts as a transcriptional repressor, and its CVC domain contributes to the DNA binding and repression that the closely related CHX10 also performs. A keratoconus-associated homeodomain change, R166W, impairs DNA binding and hinders repressor function, which is the demonstration that VSX1 repression is disruptable by a coding change. Whether A256S does anything of the sort has not been tested.
VSX1 hgnc:12723 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves VSX1 (hgnc:12723). hgnc:12723 is a gene from the HUGO Gene Nomenclature Committee.
DNA-binding transcription repressor activity GO:0001227 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased DNA-binding transcription repressor activity, annotated with DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227). GO:0001227 is a molecular function from the Gene Ontology. ↓ DECREASED
Downstream
Retinal and Auditory Bipolar Cell Dysfunction VSX1 is expressed in retinal bipolar cells and controls their terminal gene expression, so a change in its repressor function has a route to bipolar cell dysfunction. The intermediate steps in this family were not measured.
Corneal Endothelial Dysgenesis
Midline Craniofacial and Sellar Maldevelopment
Show evidence (3 references)
PMID:15647262 SUPPORT INDIRECT In Vitro
"VSX1 contains closely related homeo and CVC domains and, like CHX10, also repressed transcription."
That VSX1 is a repressor and that the CVC domain is one of its functional domains. INDIRECT because it establishes the machinery rather than what this family's change does to it.
PMID:15647262 SUPPORT INDIRECT In Vitro
"A VSX1 HD mutation, R166W, that impairs DNA binding and causes keratoconus in humans, hindered repressor function."
The proof of principle that a disease-associated VSX1 coding change can impair repression - for a different change, in a different domain, in a different disease.
PMID:30535423 REFUTE In Vitro
"In vitro analysis of additional VSX1 missense mutations showed that they either enhanced repressor activity or did not alter activity."
The counterweight, kept on the node it argues against. Tested VSX1 missense changes do not reduce repression, so a loss-of-repression reading for an untested change in this gene runs against the available functional data rather than with it.
Retinal and Auditory Bipolar Cell Dysfunction
The one part of this phenotype with support outside the family. Electrophysiology found evidence of abnormal cone bipolar cells on visual evoked response and electroretinogram in the affected adults, and of abnormal auditory bipolar cells on audiogram and auditory evoked brainstem response in the proband. Independently, Vsx1 controls terminal gene expression in type 7 ON bipolar cells in mouse, and abnormal inner-retinal function on electroretinography has been reported in carriers of two other VSX1 changes in an unrelated family - the one place where the VSX1-to-retina link has been seen twice.
retinal bipolar neuron CL:0000748 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves retinal bipolar neuron (CL:0000748). CL:0000748 is a cell type from the Cell Ontology.
retina UBERON:0000966 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in retina (UBERON:0000966). UBERON:0000966 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Abnormal Electroretinogram
Abnormal Auditory Evoked Potentials
Show evidence (3 references)
PMID:15051220 SUPPORT Human Clinical
"Electrophysiologic examination provided evidence for abnormal cone bipolar cells (visual evoked response and electroretinogram) in the adult affected patients and for abnormal auditory bipolar cells (audiogram and audio-evoked brainstem response) in the propositus."
The measurement in the family, and the two modalities used for each of the two cell populations.
PMID:21917795 SUPPORT INDIRECT Model Organism
"In the absence of Vsx1, Type 7 bipolar cells exhibit proper morphological specification but show defects in terminal gene expression."
That losing Vsx1 does something specific to bipolar cells, which is what makes the family's electrophysiology mechanistically plausible rather than coincidental. INDIRECT because it is a mouse null rather than this family's allele.
PMID:11978762 SUPPORT INDIRECT Human Clinical
"However, with either the G160D or P247R mutation, electroretinography detected abnormal function of the inner retina, where VSX1 is expressed."
The same class of finding in a different family with different VSX1 changes, which is the only independent human replication of any part of this phenotype. INDIRECT because the family and the alleles are different.
Corneal Endothelial Dysgenesis
Mechanism confidence: Provisional
Anterior segment anomalies of the corneal endothelium were a constant finding in all four affected family members, and the authors take the change to reflect anomalous development of the corneal endothelium. Nothing beyond the family supports a VSX1 role here, and one substantial piece of evidence runs against it: a mouse carrying the equivalent of the VSX1 CVC-domain change p.P247R had no observable corneal defect.
corneal endothelium UBERON:0001985 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in corneal endothelium (UBERON:0001985). UBERON:0001985 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Abnormal Corneal Endothelium Morphology
Show evidence (3 references)
PMID:15051220 SUPPORT Human Clinical
"Anterior segment anomalies of the corneal endothelium were a constant finding in all affected family members."
The finding, and that it was the only one present in every affected member.
PMID:30535423 REFUTE Model Organism
"A mouse model for VSX1 p.P247R did not have any observable corneal defect, but did exhibit an abnormal electroretinogram response characterized by a more prominent ON as opposed to OFF panretinal responsiveness."
The counter-evidence, and it splits the phenotype in an informative way - the same mouse reproduces the retinal abnormality and not the corneal one, which is the pattern this entry's confidence markings follow.
PMID:30535423 REFUTE Model Organism
"While we cannot exclude a role for VSX1 as a risk factor for corneal disease, on its own, it does not appear to play a major causative role."
The authors' own conclusion about VSX1 and corneal disease, at the strength they give it - they do not exclude a contributory role, and they do exclude a major causative one.
Midline Craniofacial and Sellar Maldevelopment
Mechanism confidence: Provisional
The part of the phenotype with no proposed mechanism at all. All four affected members had craniofacial features - wide interpupillary distance and unusual pinnae. Neuroimaging found an empty sella turcica, a posterior fossa cyst, an anterior encephalocele, hypertelorism and severe hydrocephalus in the proband; a partially empty sella with a small pituitary and hypertelorism in her mother; and hypertelorism with otherwise normal imaging in her older sister. The authors conclude that the mutation results in abnormal craniofacial features and absence of the roof of the sella turcica, but propose no route from a retinal transcription factor to a midline skull-base defect, and none is invented here.
sella turcica UBERON:0003689 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in sella turcica (UBERON:0003689). UBERON:0003689 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Hypertelorism
Abnormal Pinna Morphology
Empty Sella Turcica
Hydrocephalus
Show evidence (2 references)
PMID:15051220 SUPPORT Human Clinical
"Craniofacial features, including wide interpupillary distance and unusual pinnae, occurred in the 4 affected patients."
The craniofacial findings with the denominator, which is the whole affected sibship.
PMID:15051220 SUPPORT Human Clinical
"The new mutation in the VSX1 (RINX) gene described in this report results in abnormal craniofacial features, absence of the roof of the sella turcica, and anomalous development of the corneal endothelium."
The authors' causal conclusion, quoted at the strength they state it. It is an attribution rather than a demonstration, which is why this node is PROVISIONAL.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Ear 1
Abnormal Pinna Morphology OBLIGATE HP:0000377 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Unusual pinnae, annotated with Abnormal pinna morphology (HP:0000377). HP:0000377 is a phenotype from the Human Phenotype Ontology.
Four of four in one family. Bound to the general HPO pinna term because the source says only "unusual pinnae" - any more specific binding would add detail the report does not contain. As with the other bands here, the denominator is four people in one pedigree.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Craniofacial features, including wide interpupillary distance and unusual pinnae, occurred in the 4 affected patients."
The finding in all four, in the same sentence as the interpupillary distance.
Eye 3
Hypertelorism OBLIGATE HP:0000316 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypertelorism (HP:0000316). HP:0000316 is a phenotype from the Human Phenotype Ontology.
Four of four affected members of one family, hence OBLIGATE rather than VERY_FREQUENT. The denominator is four people in one pedigree and the band records that no affected member lacked the finding, not that none ever will. In a series this small the band carries very little information and should not be read as a population frequency.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Craniofacial features, including wide interpupillary distance and unusual pinnae, occurred in the 4 affected patients."
The finding in all four, in the sentence that also carries the pinna abnormality.
Abnormal Corneal Endothelium Morphology OBLIGATE HP:0011488 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anterior segment anomalies of the corneal endothelium, annotated with Abnormal corneal endothelium morphology (HP:0011488). HP:0011488 is a phenotype from the Human Phenotype Ontology.
Four of four in one family, described by the source as constant. The band is OBLIGATE within the pedigree. It is worth reading alongside the mouse model of a VSX1 CVC-domain change, which had no observable corneal defect - the corneal claim is the one this entry hedges most heavily, and the hedge lives in the Corneal Endothelial Dysgenesis node.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Anterior segment anomalies of the corneal endothelium were a constant finding in all affected family members."
The finding and the source's own word for its consistency within the family.
Abnormal Electroretinogram FREQUENT HP:0000512 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal cone bipolar cell response on electroretinogram, annotated with Abnormal electroretinogram (HP:0000512). HP:0000512 is a phenotype from the Human Phenotype Ontology.
Three of the four affected members are adults and the electrophysiology is reported for the adults, so 3/4, inside the FREQUENT band. The affected child is the proband, and the source reports her auditory rather than her retinal electrophysiology, so she is neither a positive nor a negative for this finding. As elsewhere in this entry the denominator is one family.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Electrophysiologic examination provided evidence for abnormal cone bipolar cells (visual evoked response and electroretinogram) in the adult affected patients and for abnormal auditory bipolar cells (audiogram and audio-evoked brainstem response) in the propositus."
The retinal electrophysiology and the group it was performed in, in the same sentence as the auditory findings.
Head and Neck 1
Empty Sella Turcica FREQUENT HP:6000483 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Empty sella turcica (HP:6000483). HP:6000483 is a phenotype from the Human Phenotype Ontology.
Two of four affected members, so 2/4, inside the FREQUENT band. The two are not identical - one sella is empty and the other partially so - and the third affected member imaged had normal neuroimaging apart from hypertelorism, which is recorded here so the band is not read as a uniform finding.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"her mother had a partially empty sella turcica, a small pituitary gland without any subarachnoid extension of fluid, and hypertelorism; and her older sister had hypertelorism but otherwise normal neuroimaging results"
The second affected member's sella finding, and in the same sentence the third member's normal imaging - which is what bounds the band at two of four.
Nervous System 2
Hydrocephalus OCCASIONAL HP:0000238 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Severe hydrocephalus, annotated with Hydrocephalus (HP:0000238). HP:0000238 is a phenotype from the Human Phenotype Ontology.
One of four affected members, so 1/4 or 25 percent, inside the OCCASIONAL band. It is a count in a four-person pedigree, not a population frequency. The posterior fossa cyst and anterior encephalocele reported in the same child are described in the pathophysiology node rather than bound separately, because they are not separable from this finding in a single individual.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Neuroimaging demonstrated that the propositus had an empty sella turcica, a posterior fossa cyst, an anterior encephalocele, hypertelorism, and severe hydrocephalus"
The proband's full neuroimaging picture, which is the most severe in the family by a wide margin.
Abnormal Auditory Evoked Potentials OCCASIONAL HP:0006958 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal auditory brainstem response, annotated with Abnormal auditory evoked potentials (HP:0006958). HP:0006958 is a phenotype from the Human Phenotype Ontology.
Reported in the proband alone, so 1/4 or 25 percent, inside the OCCASIONAL band. The other three affected members are not recorded as having had auditory testing, so this is one positive out of one tested rather than one out of four assessed - the band uses the affected denominator for consistency with the rest of the entry and should not be read as a rate.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Electrophysiologic examination provided evidence for abnormal cone bipolar cells (visual evoked response and electroretinogram) in the adult affected patients and for abnormal auditory bipolar cells (audiogram and audio-evoked brainstem response) in the propositus."
The auditory half of the same electrophysiological workup, in the one child tested.
🧬

Genetic Associations

1
VSX1
Gene: VSX1 hgnc:12723 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is VSX1 (hgnc:12723). hgnc:12723 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: DISPUTED variant_origin: GERMLINE
Show evidence (3 references)
PMID:15051220 SUPPORT Human Clinical
"To present a previously unreported African American family with 1 variation and 1 mutation of the homeobox transcription factor gene, VSX1 (RINX), and to describe the clinical features of family members."
The study's own statement of what it found - one variation and one mutation, in one family - which is the whole basis of the gene-disease claim.
PMID:30535423 REFUTE Model Organism
"While we cannot exclude a role for VSX1 as a risk factor for corneal disease, on its own, it does not appear to play a major causative role."
The most direct challenge to a causative typing, from the study that built a mouse to test it. It bears on the corneal half of this phenotype specifically.
PMID:16799019 REFUTE Human Clinical
"The absence of pathogenic mutations in the VSX1 gene in a large number of unrelated KTCN patients indicates that other genetic factors are involved in the development of this disorder."
A negative cohort study of the gene's best-known association. It does not test this syndrome, and it is cited because the cumulative weakening of VSX1's disease associations is part of why this entry types the gene DISPUTED.
🔬

Diagnosis

1
No established diagnostic pathway
There is none to describe. The single reported family was ascertained clinically and genotyped by direct sequencing of VSX1 in all available members. No diagnostic criteria have been proposed, no second family has been diagnosed, and the combination of findings that defines the entity - craniofacial features, corneal endothelial anomalies, an empty sella and abnormal bipolar cell electrophysiology - has not been assembled in anyone outside this pedigree. A clinician who found this constellation today would be making the same judgement the original authors made, without the benefit of a second case.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"Blood was drawn from all available family members, and the VSX1 (RINX) gene was sequenced."
The genetic method, which was candidate-gene sequencing of VSX1 rather than an unbiased search - so the gene was chosen before the variant was found.
📊

Prevalence

1
Worldwide
Cases In Literature <1 in 1,000,000
Four affected members of one three-generation family, in a single 2004 report. A PubMed search on 2026-09-08 for the syndrome name, and for VSX1 combined with craniofacial, anterior segment, sella and CVC-domain terms, returned no second family and no follow-up on this one. No population estimate exists and none is possible from a single pedigree ascertained through an ophthalmology clinic. The prevalence_class is the numeric floor tier; no rate_per_100000 is given because none has been reported. Read the tier as a statement about how few cases are on record, not as an estimate of how many exist.
Show evidence (1 reference)
PMID:15051220 SUPPORT Human Clinical
"A 3-generation family with 7 available family members."
The entire evidence base for this entity, stated as the study's participant count.
{ }

Source YAML

click to show 
name: Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome
category: Mendelian
creation_date: "2026-09-08T00:00:00Z"
synonyms:
- CAASDS
- craniofacial anomalies and anterior segment dysgenesis syndrome
- VSX1-related craniofacial and anterior segment syndrome
disease_term:
  preferred_term: craniofacial anomalies and anterior segment dysgenesis syndrome
  term:
    id: MONDO:0013618
    label: craniofacial anomalies and anterior segment dysgenesis syndrome
description: >-
  CAASDS (OMIM 614195) rests on a single publication: one three-generation African American
  family, four affected members, reported in 2004. A PubMed search on 2026-09-08 for the
  syndrome name, and for VSX1 with craniofacial or anterior segment terms, returned no
  second family in the twenty-two years since. This entry is therefore as much about the
  limits of the evidence as about the disease, and it is written that way rather than
  presenting a four-person phenotype as an established entity.

  What the family shows is consistent. Craniofacial features - wide interpupillary distance
  and unusual pinnae - were present in all four affected members, and anterior segment
  anomalies of the corneal endothelium were described as a constant finding in all of them.
  Beyond that the expressivity is extreme: the proband had an empty sella turcica, a
  posterior fossa cyst, an anterior encephalocele and severe hydrocephalus, her mother had a
  partially empty sella with a small pituitary and hypertelorism, and her older sister had
  hypertelorism and otherwise normal neuroimaging. Electrophysiology found abnormal cone
  bipolar cell function in the affected adults and abnormal auditory bipolar cell function in
  the proband.

  Two VSX1 changes segregate with the phenotype, and they sit on the same chromosome: R131S,
  which the authors classify as a variation outside a critical region and present in a few
  controls, and A256S, in the conserved CVC domain and absent from controls. Only the second
  is offered as the mutation. That matters, because R131S is catalogued elsewhere as a
  previously reported single-nucleotide polymorphism, found in a keratoconus cohort in which
  no VSX1 variant proved pathogenic.

  The gene's disease associations are contested more broadly, and this entry carries that
  context because it bears directly on how much weight the entity can take. VSX1 was
  originally reported for posterior polymorphous corneal dystrophy and keratoconus; dismech
  already records those assignments as unconfirmed or of uncertain significance in
  Posterior_Polymorphous_Corneal_Dystrophy, and types VSX1 as DISPUTED in Keratoconus. A
  mouse carrying the equivalent of the VSX1 CVC-domain change p.P247R has no corneal defect
  at all, though it does have an abnormal electroretinogram, and the authors of that study
  conclude that VSX1 on its own does not appear to play a major causative role in corneal
  disease. There is no ClinGen gene-disease validity assertion for VSX1.

  The one part of this phenotype with independent mechanistic support is the retinal
  electrophysiology. VSX1 is a paired-like homeodomain transcriptional repressor expressed in
  retinal bipolar cells; it regulates terminal differentiation of type 7 ON bipolar cells in
  mouse, and abnormal inner-retinal function on electroretinography has been reported in
  carriers of two other VSX1 changes in an unrelated family. The craniofacial and sellar
  findings have no proposed mechanism in any source read here, and none is invented.
parents:
- Anterior segment dysgenesis
- Hereditary disease
classifications:
  harrisons_chapter:
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    notes: >-
      Reported as a Mendelian, gene-attributed syndrome, though the gene-disease
      relationship rests on one family and has never been independently assessed.
  - classification_value: OTHER
    notes: >-
      The dominant organ system is the eye - anterior segment anomalies of the corneal
      endothelium were present in every affected family member, and the retinal
      electrophysiology is the only part of the phenotype with independent mechanistic
      support. HarrisonsChapterEnum has no ophthalmology value, so OTHER is used rather than
      forcing the entity into a Part it does not belong to.
references:
- reference: PMID:15051220
  title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
- reference: PMID:11978762
  title: "VSX1: a gene for posterior polymorphous dystrophy and keratoconus."
- reference: PMID:15647262
  title: "Transcriptional activity of the paired-like homeodomain proteins CHX10 and VSX1."
- reference: PMID:21917795
  title: "Vsx1 regulates terminal differentiation of type 7 ON bipolar cells."
- reference: PMID:30535423
  title: "Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease."
- reference: PMID:16799019
  title: "No VSX1 gene mutations associated with keratoconus."
inheritance:
- name: Autosomal dominant inheritance
  description: >-
    The two VSX1 changes were present on one chromosome at 20p11.2 and segregated with the
    four affected members of a three-generation pedigree, which is a dominant pattern in a
    single family. Nothing stronger can be said: there is no second family, no de novo event,
    and no functional demonstration that either change is pathogenic. Expressivity within
    the family is described by the authors as extremely variable, so the pattern is
    segregation in one pedigree rather than an established mode of inheritance.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Both were present on 1 chromosome at 20p11.2 and were segregated with the 4 affected patients."
    explanation: >-
      The segregation evidence, and the fact that the two changes travel together on one
      chromosome rather than as independent alleles.
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical features demonstrated extremely variable expressivity."
    explanation: >-
      The authors' own summary of how differently the same genotype presented within one
      family, which is what makes any frequency claim from this series fragile.
pathophysiology:
- name: VSX1 CVC-Domain Substitution in cis with a Coding Variant
  biological_scale: MOLECULAR
  description: >-
    Two changes in VSX1, on the same chromosome, in all four affected members. R131S lies
    outside a critical region and was found in a few controls, and the authors class it as a
    variation rather than a mutation; A256S falls in the conserved CVC domain and was found
    in no control. Only A256S is offered as the causal change. The distinction is not
    academic: R131S is independently catalogued as a previously reported single-nucleotide
    polymorphism in a keratoconus cohort in which no VSX1 variant proved pathogenic.
  genes:
  - preferred_term: VSX1
    term:
      id: hgnc:12723
      label: VSX1
  genetic_context:
    genes:
    - preferred_term: VSX1
      term:
        id: hgnc:12723
        label: VSX1
    allele_type: two coding substitutions in cis, R131S and A256S, the latter in the CVC domain
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    description: >-
      Heterozygous in all four affected members of one pedigree, both changes on the same
      chromosome. No second family has been reported.
    notes: >-
      No functional_impact_category is recorded, and that is deliberate. Neither change has
      been functionally characterised. The published in vitro work on VSX1 covers the
      homeodomain change R166W, which impairs DNA binding and hinders repressor function, and
      a set of missense changes that either enhanced repressor activity or left it unaltered -
      A256S is not among them. Assigning LOSS_OF_FUNCTION or GAIN_OF_FUNCTION here would be an
      inference from domain position rather than a measurement, and the direction is not even
      predictable: the closest characterised CVC-domain change, P247R, enhanced rather than
      reduced repressor activity.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two changes in VSX1 (RINX) were identified: a variation (R131S) not in a critical region and in few controls, and a mutation (A256S) in the critical CVC-domain and not in any controls."
    explanation: >-
      Both changes with the authors' own classification of each, which is the reason this
      entry treats only one of the two as a candidate cause.
  - reference: PMID:16799019
    reference_title: "No VSX1 gene mutations associated with keratoconus."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two previously reported SNPs were also identified: c.426C>A (Arg131Ser) in one affected patient and c.581A>G (Ala182Ala) in 51 of the 100 affected patients."
    explanation: >-
      Independent evidence that R131S circulates as a polymorphism. INDIRECT because the
      cohort is a keratoconus series rather than this syndrome, but it is the same nucleotide
      change and it bears directly on how much of this genotype can be doing any work.
  downstream:
  - target: Impaired VSX1 Transcriptional Repression
    causal_link_type: DIRECT
- name: Impaired VSX1 Transcriptional Repression
  biological_scale: MOLECULAR
  description: >-
    VSX1 is a paired-like homeodomain protein that acts as a transcriptional repressor, and
    its CVC domain contributes to the DNA binding and repression that the closely related
    CHX10 also performs. A keratoconus-associated homeodomain change, R166W, impairs DNA
    binding and hinders repressor function, which is the demonstration that VSX1 repression
    is disruptable by a coding change. Whether A256S does anything of the sort has not been
    tested.
  genes:
  - preferred_term: VSX1
    term:
      id: hgnc:12723
      label: VSX1
  molecular_functions:
  - preferred_term: DNA-binding transcription repressor activity
    modifier: DECREASED
    term:
      id: GO:0001227
      label: "DNA-binding transcription repressor activity, RNA polymerase II-specific"
  mechanism_confidence: PROVISIONAL
  notes: >-
    PROVISIONAL, and the reason is worth stating plainly: this node is an inference from
    domain position, not a measurement. The repression machinery is real and the CVC domain
    is part of it, but no functional study of A256S exists. Worse for the naive reading, the
    direction is not predictable from what has been tested - a later survey of VSX1 missense
    changes found that they either enhanced repressor activity or did not alter it, and the
    CVC-domain change P247R enhanced it. So the modifier here records the direction this
    entry's causal chain would need rather than one that has been observed for this allele,
    and a reviewer should treat it as a hypothesis.
  evidence:
  - reference: PMID:15647262
    reference_title: "Transcriptional activity of the paired-like homeodomain proteins CHX10 and VSX1."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "VSX1 contains closely related homeo and CVC domains and, like CHX10, also repressed transcription."
    explanation: >-
      That VSX1 is a repressor and that the CVC domain is one of its functional domains.
      INDIRECT because it establishes the machinery rather than what this family's change
      does to it.
  - reference: PMID:15647262
    reference_title: "Transcriptional activity of the paired-like homeodomain proteins CHX10 and VSX1."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "A VSX1 HD mutation, R166W, that impairs DNA binding and causes keratoconus in humans, hindered repressor function."
    explanation: >-
      The proof of principle that a disease-associated VSX1 coding change can impair
      repression - for a different change, in a different domain, in a different disease.
  - reference: PMID:30535423
    reference_title: "Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease."
    supports: REFUTE
    evidence_source: IN_VITRO
    snippet: "In vitro analysis of additional VSX1 missense mutations showed that they either enhanced repressor activity or did not alter activity."
    explanation: >-
      The counterweight, kept on the node it argues against. Tested VSX1 missense changes do
      not reduce repression, so a loss-of-repression reading for an untested change in this
      gene runs against the available functional data rather than with it.
  downstream:
  - target: Retinal and Auditory Bipolar Cell Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      VSX1 is expressed in retinal bipolar cells and controls their terminal gene expression,
      so a change in its repressor function has a route to bipolar cell dysfunction. The
      intermediate steps in this family were not measured.
  - target: Corneal Endothelial Dysgenesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Midline Craniofacial and Sellar Maldevelopment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Retinal and Auditory Bipolar Cell Dysfunction
  biological_scale: CELLULAR
  description: >-
    The one part of this phenotype with support outside the family. Electrophysiology found
    evidence of abnormal cone bipolar cells on visual evoked response and electroretinogram
    in the affected adults, and of abnormal auditory bipolar cells on audiogram and auditory
    evoked brainstem response in the proband. Independently, Vsx1 controls terminal gene
    expression in type 7 ON bipolar cells in mouse, and abnormal inner-retinal function on
    electroretinography has been reported in carriers of two other VSX1 changes in an
    unrelated family - the one place where the VSX1-to-retina link has been seen twice.
  cell_types:
  - preferred_term: retinal bipolar neuron
    term:
      id: CL:0000748
      label: retinal bipolar neuron
  locations:
  - preferred_term: retina
    term:
      id: UBERON:0000966
      label: retina
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Electrophysiologic examination provided evidence for abnormal cone bipolar cells (visual evoked response and electroretinogram) in the adult affected patients and for abnormal auditory bipolar cells (audiogram and audio-evoked brainstem response) in the propositus."
    explanation: >-
      The measurement in the family, and the two modalities used for each of the two cell
      populations.
  - reference: PMID:21917795
    reference_title: "Vsx1 regulates terminal differentiation of type 7 ON bipolar cells."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "In the absence of Vsx1, Type 7 bipolar cells exhibit proper morphological specification but show defects in terminal gene expression."
    explanation: >-
      That losing Vsx1 does something specific to bipolar cells, which is what makes the
      family's electrophysiology mechanistically plausible rather than coincidental. INDIRECT
      because it is a mouse null rather than this family's allele.
  - reference: PMID:11978762
    reference_title: "VSX1: a gene for posterior polymorphous dystrophy and keratoconus."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, with either the G160D or P247R mutation, electroretinography detected abnormal function of the inner retina, where VSX1 is expressed."
    explanation: >-
      The same class of finding in a different family with different VSX1 changes, which is
      the only independent human replication of any part of this phenotype. INDIRECT because
      the family and the alleles are different.
  downstream:
  - target: Abnormal Electroretinogram
  - target: Abnormal Auditory Evoked Potentials
- name: Corneal Endothelial Dysgenesis
  biological_scale: TISSUE
  description: >-
    Anterior segment anomalies of the corneal endothelium were a constant finding in all four
    affected family members, and the authors take the change to reflect anomalous development
    of the corneal endothelium. Nothing beyond the family supports a VSX1 role here, and one
    substantial piece of evidence runs against it: a mouse carrying the equivalent of the
    VSX1 CVC-domain change p.P247R had no observable corneal defect.
  locations:
  - preferred_term: corneal endothelium
    term:
      id: UBERON:0001985
      label: corneal endothelium
  mechanism_confidence: PROVISIONAL
  notes: >-
    PROVISIONAL because the finding is consistent within one family and contradicted outside
    it. dismech already records VSX1's corneal assignments as unconfirmed or of uncertain
    significance in Posterior_Polymorphous_Corneal_Dystrophy and types the gene DISPUTED in
    Keratoconus, and the mouse model of a CVC-domain change has no corneal phenotype. The
    node is kept because the observation in this family is real and reported in every
    affected member; the incoming edge is marked as having unknown intermediates because no
    step between a transcription factor and a corneal endothelial phenotype has been shown.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Anterior segment anomalies of the corneal endothelium were a constant finding in all affected family members."
    explanation: The finding, and that it was the only one present in every affected member.
  - reference: PMID:30535423
    reference_title: "Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "A mouse model for VSX1 p.P247R did not have any observable corneal defect, but did exhibit an abnormal electroretinogram response characterized by a more prominent ON as opposed to OFF panretinal responsiveness."
    explanation: >-
      The counter-evidence, and it splits the phenotype in an informative way - the same
      mouse reproduces the retinal abnormality and not the corneal one, which is the pattern
      this entry's confidence markings follow.
  - reference: PMID:30535423
    reference_title: "Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "While we cannot exclude a role for VSX1 as a risk factor for corneal disease, on its own, it does not appear to play a major causative role."
    explanation: >-
      The authors' own conclusion about VSX1 and corneal disease, at the strength they give
      it - they do not exclude a contributory role, and they do exclude a major causative one.
  downstream:
  - target: Abnormal Corneal Endothelium Morphology
- name: Midline Craniofacial and Sellar Maldevelopment
  biological_scale: TISSUE
  description: >-
    The part of the phenotype with no proposed mechanism at all. All four affected members
    had craniofacial features - wide interpupillary distance and unusual pinnae. Neuroimaging
    found an empty sella turcica, a posterior fossa cyst, an anterior encephalocele,
    hypertelorism and severe hydrocephalus in the proband; a partially empty sella with a
    small pituitary and hypertelorism in her mother; and hypertelorism with otherwise normal
    imaging in her older sister. The authors conclude that the mutation results in abnormal
    craniofacial features and absence of the roof of the sella turcica, but propose no route
    from a retinal transcription factor to a midline skull-base defect, and none is invented
    here.
  locations:
  - preferred_term: sella turcica
    term:
      id: UBERON:0003689
      label: sella turcica
  mechanism_confidence: PROVISIONAL
  notes: >-
    PROVISIONAL, and this is the weakest node in the entry. VSX1 is a retinal and spinal
    interneuron transcription factor; no source read here proposes a craniofacial or
    skull-base role for it, no animal model shows one, and the finding rests on imaging of
    three individuals in one family. The posterior fossa cyst and the anterior encephalocele
    are described in prose rather than bound as phenotypes because each was seen in one
    person and neither is separable from the severe hydrocephalus in the same child.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial features, including wide interpupillary distance and unusual pinnae, occurred in the 4 affected patients."
    explanation: The craniofacial findings with the denominator, which is the whole affected sibship.
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The new mutation in the VSX1 (RINX) gene described in this report results in abnormal craniofacial features, absence of the roof of the sella turcica, and anomalous development of the corneal endothelium."
    explanation: >-
      The authors' causal conclusion, quoted at the strength they state it. It is an
      attribution rather than a demonstration, which is why this node is PROVISIONAL.
  downstream:
  - target: Hypertelorism
  - target: Abnormal Pinna Morphology
  - target: Empty Sella Turcica
  - target: Hydrocephalus
phenotypes:
- name: Hypertelorism
  category: Head and Neck
  description: >-
    Wide interpupillary distance in all four affected members, and hypertelorism specifically
    recorded on neuroimaging in the proband, her mother and her older sister.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  notes: >-
    Four of four affected members of one family, hence OBLIGATE rather than VERY_FREQUENT.
    The denominator is four people in one pedigree and the band records that no affected
    member lacked the finding, not that none ever will. In a series this small the band
    carries very little information and should not be read as a population frequency.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial features, including wide interpupillary distance and unusual pinnae, occurred in the 4 affected patients."
    explanation: The finding in all four, in the sentence that also carries the pinna abnormality.
- name: Abnormal Pinna Morphology
  category: Head and Neck
  description: >-
    Unusual pinnae in all four affected members. The source describes them no further, so
    neither the shape nor the laterality is recorded here.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Unusual pinnae
    term:
      id: HP:0000377
      label: Abnormal pinna morphology
  notes: >-
    Four of four in one family. Bound to the general HPO pinna term because the source says
    only "unusual pinnae" - any more specific binding would add detail the report does not
    contain. As with the other bands here, the denominator is four people in one pedigree.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Craniofacial features, including wide interpupillary distance and unusual pinnae, occurred in the 4 affected patients."
    explanation: The finding in all four, in the same sentence as the interpupillary distance.
- name: Abnormal Corneal Endothelium Morphology
  category: Eye
  description: >-
    Anterior segment anomalies of the corneal endothelium, described as a constant finding in
    all affected family members. This is the anterior segment dysgenesis the syndrome is named
    for.
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: Anterior segment anomalies of the corneal endothelium
    term:
      id: HP:0011488
      label: Abnormal corneal endothelium morphology
  notes: >-
    Four of four in one family, described by the source as constant. The band is OBLIGATE
    within the pedigree. It is worth reading alongside the mouse model of a VSX1 CVC-domain
    change, which had no observable corneal defect - the corneal claim is the one this entry
    hedges most heavily, and the hedge lives in the Corneal Endothelial Dysgenesis node.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Anterior segment anomalies of the corneal endothelium were a constant finding in all affected family members."
    explanation: The finding and the source's own word for its consistency within the family.
- name: Empty Sella Turcica
  category: Nervous System
  description: >-
    An empty sella turcica in the proband and a partially empty sella with a small pituitary
    gland, without subarachnoid extension of fluid, in her mother. The authors describe the
    lesion as absence of the roof of the sella turcica.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Empty sella turcica
    term:
      id: HP:6000483
      label: Empty sella turcica
  notes: >-
    Two of four affected members, so 2/4, inside the FREQUENT band. The two are not identical
    - one sella is empty and the other partially so - and the third affected member imaged
    had normal neuroimaging apart from hypertelorism, which is recorded here so the band is
    not read as a uniform finding.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "her mother had a partially empty sella turcica, a small pituitary gland without any subarachnoid extension of fluid, and hypertelorism; and her older sister had hypertelorism but otherwise normal neuroimaging results"
    explanation: >-
      The second affected member's sella finding, and in the same sentence the third
      member's normal imaging - which is what bounds the band at two of four.
- name: Hydrocephalus
  category: Nervous System
  description: >-
    Severe hydrocephalus in the proband, alongside a posterior fossa cyst and an anterior
    encephalocele on the same neuroimaging study.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Severe hydrocephalus
    term:
      id: HP:0000238
      label: Hydrocephalus
  notes: >-
    One of four affected members, so 1/4 or 25 percent, inside the OCCASIONAL band. It is a
    count in a four-person pedigree, not a population frequency. The posterior fossa cyst and
    anterior encephalocele reported in the same child are described in the pathophysiology
    node rather than bound separately, because they are not separable from this finding in a
    single individual.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neuroimaging demonstrated that the propositus had an empty sella turcica, a posterior fossa cyst, an anterior encephalocele, hypertelorism, and severe hydrocephalus"
    explanation: >-
      The proband's full neuroimaging picture, which is the most severe in the family by a
      wide margin.
- name: Abnormal Electroretinogram
  category: Eye
  description: >-
    Evidence of abnormal cone bipolar cell function on visual evoked response and
    electroretinogram in the affected adults.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Abnormal cone bipolar cell response on electroretinogram
    term:
      id: HP:0000512
      label: Abnormal electroretinogram
  notes: >-
    Three of the four affected members are adults and the electrophysiology is reported for
    the adults, so 3/4, inside the FREQUENT band. The affected child is the proband, and the
    source reports her auditory rather than her retinal electrophysiology, so she is neither
    a positive nor a negative for this finding. As elsewhere in this entry the denominator is
    one family.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Electrophysiologic examination provided evidence for abnormal cone bipolar cells (visual evoked response and electroretinogram) in the adult affected patients and for abnormal auditory bipolar cells (audiogram and audio-evoked brainstem response) in the propositus."
    explanation: >-
      The retinal electrophysiology and the group it was performed in, in the same sentence
      as the auditory findings.
- name: Abnormal Auditory Evoked Potentials
  category: Ear
  description: >-
    Evidence of abnormal auditory bipolar cell function on audiogram and auditory evoked
    brainstem response in the proband.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Abnormal auditory brainstem response
    term:
      id: HP:0006958
      label: Abnormal auditory evoked potentials
  notes: >-
    Reported in the proband alone, so 1/4 or 25 percent, inside the OCCASIONAL band. The
    other three affected members are not recorded as having had auditory testing, so this is
    one positive out of one tested rather than one out of four assessed - the band uses the
    affected denominator for consistency with the rest of the entry and should not be read
    as a rate.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Electrophysiologic examination provided evidence for abnormal cone bipolar cells (visual evoked response and electroretinogram) in the adult affected patients and for abnormal auditory bipolar cells (audiogram and audio-evoked brainstem response) in the propositus."
    explanation: The auditory half of the same electrophysiological workup, in the one child tested.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: BELOW_1_IN_1000000
  notes: >-
    Four affected members of one three-generation family, in a single 2004 report. A PubMed
    search on 2026-09-08 for the syndrome name, and for VSX1 combined with craniofacial,
    anterior segment, sella and CVC-domain terms, returned no second family and no follow-up
    on this one. No population estimate exists and none is possible from a single pedigree
    ascertained through an ophthalmology clinic. The prevalence_class is the numeric floor
    tier; no rate_per_100000 is given because none has been reported. Read the tier as a
    statement about how few cases are on record, not as an estimate of how many exist.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 3-generation family with 7 available family members."
    explanation: The entire evidence base for this entity, stated as the study's participant count.
genetic:
- name: VSX1
  relationship_type: DISPUTED
  variant_origin: GERMLINE
  gene_term:
    preferred_term: VSX1
    term:
      id: hgnc:12723
      label: VSX1
  notes: >-
    VSX1 encodes a paired-like homeodomain transcription factor with homeo and CVC domains,
    expressed in retinal bipolar cells and in spinal V2 interneuron precursors, where it acts
    as a transcriptional repressor.

    relationship_type is DISPUTED rather than CAUSATIVE, and the reasons are cumulative
    rather than any one being decisive. The syndrome rests on one family, never replicated in
    twenty-two years. The genotype is two changes in cis, one of which the reporting authors
    themselves classify as a variation and which is independently catalogued as a
    polymorphism. Neither change has been functionally characterised, and the tested VSX1
    missense changes either enhance repressor activity or leave it unchanged, so the
    direction a loss-of-function reading needs has not been observed for this gene. A mouse
    carrying the equivalent of a VSX1 CVC-domain change reproduces the retinal
    electrophysiology and not the corneal phenotype. And there is no ClinGen gene-disease
    validity assertion for VSX1 - checked against the ClinGen gene-validity download of
    2026-09-08.

    This typing is consistent with how the knowledge base already treats this gene. Keratoconus
    types VSX1 DISPUTED, and Posterior_Polymorphous_Corneal_Dystrophy records the historical
    VSX1-PPCD1 assignment as unconfirmed or of uncertain significance. Those are different
    diseases from this one, and the evidence for each is separate - but a gene whose two
    better-studied associations have both weakened over time is not one to type CAUSATIVE on
    a single unreplicated family.

    A search trap for whoever extends this entry. The VSX1 literature is dominated by
    keratoconus candidate-gene studies, most of them negative or equivocal, and by retinal and
    spinal-cord developmental biology in zebrafish, goldfish and mouse. Almost none of it
    concerns this syndrome, and a search on the gene alone will return sixty-odd records of
    which one is the entity curated here.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To present a previously unreported African American family with 1 variation and 1 mutation of the homeobox transcription factor gene, VSX1 (RINX), and to describe the clinical features of family members."
    explanation: >-
      The study's own statement of what it found - one variation and one mutation, in one
      family - which is the whole basis of the gene-disease claim.
  - reference: PMID:30535423
    reference_title: "Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "While we cannot exclude a role for VSX1 as a risk factor for corneal disease, on its own, it does not appear to play a major causative role."
    explanation: >-
      The most direct challenge to a causative typing, from the study that built a mouse to
      test it. It bears on the corneal half of this phenotype specifically.
  - reference: PMID:16799019
    reference_title: "No VSX1 gene mutations associated with keratoconus."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "The absence of pathogenic mutations in the VSX1 gene in a large number of unrelated KTCN patients indicates that other genetic factors are involved in the development of this disorder."
    explanation: >-
      A negative cohort study of the gene's best-known association. It does not test this
      syndrome, and it is cited because the cumulative weakening of VSX1's disease
      associations is part of why this entry types the gene DISPUTED.
diagnosis:
- name: No established diagnostic pathway
  description: >-
    There is none to describe. The single reported family was ascertained clinically and
    genotyped by direct sequencing of VSX1 in all available members. No diagnostic criteria
    have been proposed, no second family has been diagnosed, and the combination of findings
    that defines the entity - craniofacial features, corneal endothelial anomalies, an empty
    sella and abnormal bipolar cell electrophysiology - has not been assembled in anyone
    outside this pedigree. A clinician who found this constellation today would be making the
    same judgement the original authors made, without the benefit of a second case.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood was drawn from all available family members, and the VSX1 (RINX) gene was sequenced."
    explanation: >-
      The genetic method, which was candidate-gene sequencing of VSX1 rather than an unbiased
      search - so the gene was chosen before the variant was found.
discussions:
- discussion_id: caasds_is_this_a_real_entity
  kind: OPEN_QUESTION
  status: OPEN
  attaches_to:
  - disease#
  - "genetic#VSX1"
  prompt: >-
    Is CAASDS a distinct disease entity, or a single family's coincidence around a VSX1
    polymorphism?
  rationale: >-
    The question has to be asked because everything that would normally answer it is missing.
    One family, four affected members, one paper, 2004, and nothing since - a PubMed search on
    2026-09-08 for the syndrome name and for VSX1 with craniofacial, anterior segment and
    sella terms returned no second family. The genotype is two coding changes in cis, and the
    reporting authors classify one of them, R131S, as a variation rather than a mutation; it
    turns up elsewhere as a previously reported polymorphism in a keratoconus cohort. The
    other, A256S, sits in the conserved CVC domain and was absent from controls, which is
    suggestive and is not a functional result - the change has never been assayed.

    Three things argue the entity is real, and they should not be dismissed. The craniofacial
    features and the corneal endothelial anomalies were present in all four affected members
    and absent from the unaffected ones, which is what segregation looks like. The retinal
    electrophysiology has independent support from two directions: Vsx1 controls terminal gene
    expression in mouse type 7 ON bipolar cells, and a mouse carrying a VSX1 CVC-domain change
    has an abnormal electroretinogram. And OMIM and MONDO both carry the entity, so it is at
    least a concept other resources have accepted.

    Three argue the other way. VSX1's better-studied disease associations have weakened rather
    than strengthened - dismech already records the PPCD1 assignment as unconfirmed and types
    the gene DISPUTED in keratoconus. The same mouse that reproduces the retinal finding has
    no corneal defect, and its authors conclude VSX1 does not on its own play a major
    causative role in corneal disease. And the craniofacial and sellar half of the phenotype,
    which is what the syndrome is named for, has no proposed mechanism, no animal correlate
    and no second observation anywhere.

    The honest position, and the one this entry takes, is that the entity is curated because
    it exists as a named concept with a real published pedigree behind it, and that every
    causal claim in it is marked at the strength the source supports rather than at the
    strength the disease name implies. What would settle it is a second family, or a
    functional assay of A256S. Neither has been done.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two changes in VSX1 (RINX) were identified: a variation (R131S) not in a critical region and in few controls, and a mutation (A256S) in the critical CVC-domain and not in any controls."
    explanation: >-
      The genotype at the centre of the question, with the authors' own asymmetric
      classification of its two halves.
  - reference: PMID:16799019
    reference_title: "No VSX1 gene mutations associated with keratoconus."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Two previously reported SNPs were also identified: c.426C>A (Arg131Ser) in one affected patient and c.581A>G (Ala182Ala) in 51 of the 100 affected patients."
    explanation: >-
      That one of the two changes is a circulating polymorphism, which removes it from the
      causal account and leaves the entity resting on a single untested substitution.
  - reference: PMID:30535423
    reference_title: "Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease."
    supports: REFUTE
    evidence_source: MODEL_ORGANISM
    snippet: "A mouse model for VSX1 p.P247R did not have any observable corneal defect, but did exhibit an abnormal electroretinogram response characterized by a more prominent ON as opposed to OFF panretinal responsiveness."
    explanation: >-
      The experiment that splits this phenotype - the retinal half reproduces in a model, the
      corneal half does not.
  proposed_experiments:
  - experiment_id: exp_caasds_a256s_repressor_assay
    name: Assay A256S repressor activity against the tested VSX1 missense panel
    description: >-
      The published luciferase reporter assay for VSX1 transcriptional repression has already
      been run against a panel of VSX1 missense changes, including the CVC-domain change
      P247R. Running A256S through the same assay alongside that panel would say whether the
      one change this entity rests on does anything to repressor function, and in which
      direction. A result matching P247R - enhanced repression - would be as informative as a
      loss, because it would mean the entity's causal account has to be rewritten rather than
      confirmed.
    readouts:
    - name: VSX1 transcriptional repressor activity for A256S relative to wild type
      target: "pathophysiology#Impaired VSX1 Transcriptional Repression"
      direction: ALTERED
      interpretation: >-
        Any reproducible difference from wild type would move this node off PROVISIONAL; no
        difference would argue that A256S is not the causal change either.
    would_support:
    - "pathophysiology#Impaired VSX1 Transcriptional Repression"
    supporting_outcome:
    - >-
      Reduced repressor activity for A256S would support the causal chain this entry draws;
      unchanged or enhanced activity would leave the entity without a molecular mechanism.
- discussion_id: caasds_no_treatment_or_natural_history
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - treatments#
  prompt: >-
    Is there anything to curate about management?
  rationale: >-
    No. The source is a genotype-phenotype study, not a clinical follow-up, and it reports no
    intervention for any family member - not for the severe hydrocephalus in the proband,
    which would certainly have been managed somehow, and not for the corneal, retinal or
    auditory findings. No treatment, no outcome and no natural history is recoverable from it,
    and there is no second report to supply them.

    Generic management of the individual findings - shunting for hydrocephalus, corneal
    transplantation for endothelial failure, hearing amplification - would look plausible in a
    treatments block and would be an invention. None of it is reported of these patients, and
    importing it would assert of four people an experience recorded only of others. The
    treatments section is therefore empty, deliberately, and this discussion is why.
  evidence:
  - reference: PMID:15051220
    reference_title: "VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells."
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: "Main outcome measures included identification and molecular characterization of 1 variation and 1 mutation in VSX1 (RINX) of 4 affected family members (3 adults and 1 child)."
    explanation: >-
      The study's stated outcome measures are molecular and descriptive. Recorded as
      NO_EVIDENCE because the source does not bear on treatment at all, rather than bearing
      on it negatively.
notes: >-
  Scope decision: DISEASE, curated as a standalone entry, and the decision was close enough
  to be worth recording rather than asserting. MONDO:0013618 and OMIM 614195 both carry the
  concept - and note that 614195 is the number to use: OMIM 610256 is anterior segment
  dysgenesis 2, a different entity, and it is an easy substitution to make because the two
  names overlap. MONDO:0013618 xrefs 614195, its only superclass in MONDO is hereditary disease, and it has no descendants, so
  there is no grouping or parent entry to fold it into. The alternative was OUT_OF_SCOPE on
  the grounds that a never-replicated single-family syndrome whose gene is disputed does not
  carry a conserved pathograph. That was rejected because the entity does have one part with
  independent mechanistic support - the retinal bipolar cell electrophysiology - and because
  recording the contest is more useful than leaving a named MONDO concept with no entry and
  no note of why. The stub is deleted, since MONDO:0013618 is now bound as disease_term.

  What this entry is mostly about. The evidence base is one 2004 paper describing one
  three-generation family with four affected members, and a PubMed search on 2026-09-08 for
  the syndrome name and for VSX1 with craniofacial, anterior segment, sella and CVC-domain
  terms found no second family and no follow-up. Every frequency band in the entry is a count
  out of four people in one pedigree and says so in its own notes. Three of the five
  pathophysiology nodes are marked PROVISIONAL, and the two that are not - the genotype and
  the bipolar cell dysfunction - are the two with something outside the family behind them.

  The gene is typed DISPUTED, not CAUSATIVE. Four things drive that, and they are cumulative:
  the genotype is two changes in cis of which the reporting authors call one a variation and
  which is independently catalogued as a polymorphism; neither change has ever been
  functionally assayed; the VSX1 missense changes that have been assayed either enhance
  repressor activity or leave it unchanged, which is the opposite of the direction a
  loss-of-function account needs; and a mouse carrying a VSX1 CVC-domain change reproduces
  the retinal electrophysiology but has no corneal defect at all. There is no ClinGen
  gene-disease validity assertion for VSX1, checked directly against the ClinGen
  gene-validity download of 2026-09-08 - GTPBP3, curated in the same session, does appear
  there, so this is a real negative and not a missing file.

  Consistency with the rest of the knowledge base was checked rather than assumed.
  kb/disorders/Keratoconus.yaml already types VSX1 as DISPUTED, and
  kb/disorders/Posterior_Polymorphous_Corneal_Dystrophy.yaml records the historical
  VSX1-PPCD1 assignment as unconfirmed or of uncertain significance. Those are separate
  diseases with separate evidence and neither settles this one, but typing the gene CAUSATIVE
  here while it is DISPUTED two files away would have been inconsistent without justification.

  What is deliberately not curated. There is no treatments block: the source reports no
  intervention for anyone in the family, including the child with severe hydrocephalus, and
  importing generic management of the individual findings would assert of these four people
  an experience recorded only of others. The reasoning is in the discussion
  caasds_no_treatment_or_natural_history. There is no progression block, for the same reason -
  the study is a genotype-phenotype description with no follow-up. There are no animal models
  of this syndrome; the mouse cited here carries a different VSX1 change and was built to test
  corneal disease, so it is cited as evidence within nodes rather than curated as a model of
  this entity. There are no clinical trials, and no prevalence estimate beyond the
  cases-in-literature floor. The posterior fossa cyst and anterior encephalocele in the
  proband are described in prose rather than bound, because each was seen once and neither is
  separable from the severe hydrocephalus in the same child.

  The named-entity trap for this gene runs the other way from most. VSX1's literature is
  dominated by keratoconus candidate-gene studies - many of them negative - and by retinal and
  spinal-cord developmental biology in zebrafish, goldfish and mouse. A search on the gene
  alone returns around sixty records of which one is this syndrome. The risk here is not
  curating the wrong disease but importing the corneal-dystrophy literature's conclusions into
  an entry it does not describe, which is why the two dismech corneal entries are named
  explicitly above rather than paraphrased.
📚

References & Deep Research

References

6
PMID:15051220
VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.
No top-level findings curated for this source.
PMID:11978762
VSX1: a gene for posterior polymorphous dystrophy and keratoconus.
No top-level findings curated for this source.
PMID:15647262
Transcriptional activity of the paired-like homeodomain proteins CHX10 and VSX1.
No top-level findings curated for this source.
PMID:21917795
Vsx1 regulates terminal differentiation of type 7 ON bipolar cells.
No top-level findings curated for this source.
PMID:30535423
Investigating the Pathogenicity of VSX1 Missense Mutations and Their Association With Corneal Disease.
No top-level findings curated for this source.
PMID:16799019
No VSX1 gene mutations associated with keratoconus.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (VSX1) · 2026-09-08T19:08:37Z · View source

De novo curation of CAASDS (MONDO:0013618, OMIM 614195, VSX1) from claim issue #11472. An identifier correction worth recording: an initial draft of this entry, and the first deep-research query run for it, used OMIM 610256. That is anterior segment dysgenesis 2, a different entity whose name overlaps with this one. MONDO:0013618 xrefs OMIM 614195, which preflight-dr flagged, and the entry and the research query were both corrected. Scope decision: DISEASE, standalone, and the call was close enough to record rather than assert. MONDO:0013618 has hereditary disease as its only superclass and no descendants, so there is no grouping or parent entry to fold it into. The alternative was OUT_OF_SCOPE, on the grounds that a never-replicated single-family syndrome whose gene is disputed does not carry a conserved pathograph. That was rejected because one part of the phenotype - the retinal bipolar cell electrophysiology - does have independent mechanistic support, and because recording the contest is more useful than leaving a named MONDO concept with no entry and no note of why. The stub is deleted, since MONDO:0013618 is now bound as disease_term. Evidence base. One publication describes the entity: PMID:15051220, a 2004 report of a single three-generation African American family with four affected members. A PubMed search on 2026-09-08 for the syndrome name, and for VSX1 combined with craniofacial, anterior segment, sella and CVC-domain terms, returned no second family and no follow-up in twenty-two years. Five further references are cited for mechanism and for counter-evidence: PMID:11978762 (the original VSX1 disease report, which independently documents abnormal inner-retinal electroretinography in VSX1 variant carriers), PMID:15647262 (VSX1 as a transcriptional repressor; a keratoconus homeodomain change impairs repression), PMID:21917795 (Vsx1 controls terminal gene expression in mouse type 7 ON bipolar cells), PMID:30535423 (a mouse model of a VSX1 CVC-domain change with an abnormal ERG and no corneal defect), and PMID:16799019 (a negative keratoconus cohort that catalogues R131S as a previously reported SNP). 31 of 31 snippets verify; no DOI-prefixed references are cited, so nothing is skipped by prefix. The gene is typed DISPUTED rather than CAUSATIVE. Four cumulative reasons: the genotype is two coding changes in cis, one of which the reporting authors themselves call a variation and which is independently catalogued as a polymorphism in a keratoconus cohort; neither change has ever been functionally assayed; the VSX1 missense changes that have been assayed either enhance repressor activity or leave it unchanged, which is the opposite of the direction a loss-of-function account needs; and a mouse carrying a VSX1 CVC-domain change reproduces the retinal electrophysiology but has no corneal defect at all. There is no ClinGen gene-disease validity assertion for VSX1, checked directly against the ClinGen gene-validity download of 2026-09-08 - GTPBP3, curated in the same session, does appear in that file, so the absence is a real negative rather than a missing download. Consistency with the rest of the knowledge base was checked rather than assumed. Keratoconus already types VSX1 DISPUTED and Posterior_Polymorphous_Corneal_Dystrophy records the historical VSX1-PPCD1 assignment as unconfirmed or of uncertain significance. Those are separate diseases with separate evidence, and neither settles this one, but typing the gene CAUSATIVE here while it is DISPUTED two files away would have needed a justification this evidence cannot supply. Pathograph. Five nodes, three marked PROVISIONAL. The two that are not are the genotype and the bipolar cell dysfunction - the two with support outside the family. The repression node carries an explicit warning that its modifier records the direction the causal chain would need rather than one observed for this allele, and a REFUTE evidence item sits on that node quoting the functional survey that found VSX1 missense changes enhancing rather than reducing repression. Every phenotype has an incoming edge; there are no unwired phenotypes and no dangling targets. Term-selection note. HP:0002690 is "Large sella turcica", not empty sella; the correct term for this phenotype is HP:6000483 "Empty sella turcica", confirmed through OLS. UBERON:0001772 is "corneal epithelium", not endothelium; the corneal endothelium is UBERON:0001985. Both wrong candidates were caught before binding. What is deliberately not curated. No treatments block - the source reports no intervention for anyone in the family, including the child with severe hydrocephalus, and importing generic management of the individual findings would assert of four people an experience recorded only of others; the reasoning is in the discussion caasds_no_treatment_or_natural_history. No progression block, because the study is a genotype-phenotype description with no follow-up. No animal model record: the mouse cited here carries a different VSX1 change and was built to test corneal disease, so it appears as evidence within nodes rather than as a model of this entity. The posterior fossa cyst and anterior encephalocele in the proband are described in prose rather than bound, because each was seen once and neither is separable from the severe hydrocephalus in the same child. Every frequency band is a count out of four people in one pedigree and says so in its own notes. The three OBLIGATE bands record that no affected member lacked the finding, not that none ever will. Validation run: just validate (schema, terms, references), count-verified-snippets (31/31), check-entity-refs, check-duplicate-keys, check-causal-targets, check-enum-values, check-qualifier-terms, check-stubs, plus the whole-KB snippet ratchets and validate-disorders.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 12 citations 2026-09-08T12:27:54.641353

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS; VSX1/RINX homeobox gene, A256S CVC-domain change; OMIM 614195)
  • MONDO ID: MONDO:0013618 (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS; VSX1/RINX homeobox gene, A256S CVC-domain change; OMIM 614195) covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS)

Executive summary

CAASDS is an exceptionally rare, proposed Mendelian developmental syndrome defined principally by one 2004 report linking a heterozygous VSX1 (formerly RINX) missense variant, p.Ala256Ser (A256S) in the conserved CVC domain, with craniofacial abnormalities, corneal/anterior-segment changes, empty sella, and abnormal retinal and auditory electrophysiology. The principal primary citation is Mintz-Hittner et al., Ophthalmology 111:828–836, published April 2004, PMID: 15051220 (PubMed). Current Open Targets data map this phenotype to MONDO:0013618 and identify VSX1 as its leading associated target, but most database records ultimately reuse the same publication rather than providing independent replication. Consequently, the syndrome and especially the pathogenicity of A256S should be treated as limited-evidence assertions, not as a well-validated gene–disease relationship. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

No new human CAASDS cohort, natural-history study, prevalence estimate, disease-specific treatment, or interventional trial was identified for 2023–2024. The main recent advance is a 2023 zebrafish vsx1/vsx2 double-knockout study showing retinal-network redundancy; it is informative about VSX biology but is neither a VSX1-only model nor an A256S model. (joaquin2023mutationofvsx pages 1-3, joaquin2023mutationofvsx pages 7-10)

Domain Finding Evidence type/year Confidence / limitation Suggested ontology terms
Disease identity Craniofacial Anomalies and Anterior Segment Dysgenesis Syndrome (CAASDS); OMIM 614195; MONDO:0013618 Aggregated disease-resource annotation; current Open Targets/MONDO mapping Disease entity is recognized, but its human evidence base is extremely limited and anchored to the original report (PMID 15051220) (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1) MONDO: craniofacial anomalies and anterior segment dysgenesis syndrome; OMIM: 614195
Causal-gene association VSX1 (visual system homeobox 1; RINX; ENSG00000100987) is the principal gene associated with CAASDS Human genetic literature and database aggregation; 2004/current Moderate database-level association; repeated records trace largely to the same publication rather than independent families (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1) Suggested: VSX1; visual system homeobox 1; DNA-binding transcription factor
Reported variant VSX1 p.Ala256Ser (A256S), a missense change reported in the conserved CVC domain Human pedigree/case report, 2004; variant database record RCV000005562 Disease-defining candidate, but no retrieved validated A256S-specific functional assay; modern literature notes uncertainty surrounding pathogenicity of reported VSX1 CVC variants (zou2012vsx2controlseye pages 2-4, OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1) Suggested SO: missense variant; germline variant; suggested protein region: CVC domain
Inheritance Database annotation supports a monoallelic, autosomal or pseudoautosomal, non-imprinted requirement—consistent with reported autosomal-dominant inheritance Human segregation/database annotation; 2004/current Penetrance, phenocopies, de novo status, germline mosaicism, and recurrence risk were not established in the retrieved evidence; Genomics England confidence is “amber” (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1) Suggested HPO: Autosomal dominant inheritance
Craniofacial phenotype Craniofacial anomalies were reported as part of the defining clinical presentation Human clinical report, 2004 Reported in a very small pedigree/case series; exact frequency, onset, severity, and progression cannot be generalized (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6) Suggested HPO: Craniofacial dysmorphism; Abnormality of facial morphology
Anterior ocular phenotype Anterior-segment involvement included corneal endothelial changes, supporting the “anterior segment dysgenesis” designation Human ophthalmic evaluation, 2004 Specific laterality, quantitative endothelial findings, progression, and visual impact are not available in the retrieved excerpts (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6) Suggested HPO: Anterior segment dysgenesis; Abnormal corneal endothelium; Corneal abnormality
Sellar phenotype Empty sella was reported Human clinical/imaging report, 2004 Evidence derives from the original report; endocrine consequences and penetrance are unknown (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6) Suggested HPO: Empty sella
Retinal physiology Abnormal retinal bipolar-cell physiology/electroretinographic findings were reported; VSX1 is normally restricted to subsets of differentiated cone bipolar cells in mammals Human electrophysiology plus comparative biology; 2004/2023 Supports biological plausibility but does not prove that A256S caused the physiological abnormality (joaquin2023mutationofvsx pages 1-3) Suggested HPO: Abnormal electroretinogram; Visual impairment; suggested CL: retinal bipolar neuron; cone retinal bipolar cell
Auditory physiology Abnormal auditory bipolar-cell physiology was reported in the defining study Human auditory electrophysiology; 2004 Exact test results, clinical hearing threshold, penetrance, and natural history were not retrievable; “auditory bipolar cell” should not be conflated with retinal bipolar neurons (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6) Suggested HPO: Abnormal auditory electrophysiology; Hearing impairment
Mechanistic interpretation A256S is hypothesized to alter CVC-assisted DNA binding and transcriptional regulation, potentially disturbing developmental cell-fate programs Domain-based inference from VSX-family biology Inferred, not demonstrated for VSX1 A256S. Experimental CVC-domain effects were shown principally for VSX2, which must not be treated as direct CAASDS evidence (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4) Suggested GO: DNA-binding transcription-factor activity; regulation of transcription by RNA polymerase II; cell-fate specification; retinal development
2023 model evidence Zebrafish vsx1/vsx2 double knockout caused severe visual impairment, bipolar-cell depletion, and precursor rerouting toward photoreceptor or Müller-glial fates, while neural-retina specification persisted without microphthalmia CRISPR double-knockout zebrafish; electrophysiology, histology, RNA-seq, and ATAC-seq; 2023 Strong comparative evidence for redundant VSX functions, but not a VSX1-only or A256S knock-in model and not a model of the craniofacial/sellar phenotype (joaquin2023mutationofvsx pages 1-3, joaquin2023mutationofvsx pages 7-10) Suggested GO: retinal bipolar-cell differentiation; neural-retina development; cell-fate commitment; suggested CL: retinal bipolar neuron, photoreceptor cell, Müller glial cell
2023 molecular profiling Double-mutant zebrafish had 1,564 differentially accessible chromatin regions, but only 5% of neighboring genes were differentially expressed, indicating network robustness ATAC-seq, RNA-seq, and qPCR; 2023 Quantitative model-organism result; cannot be assigned directly to human VSX1 A256S or craniofacial tissues (joaquin2023mutationofvsx pages 7-10) Suggested GO: chromatin organization; regulation of gene expression; retinal development
Epidemiology No population prevalence, incidence, carrier frequency, sex ratio, geographic distribution, or founder effect has been established Negative evidence assessment CAASDS appears ultra-rare, but a numerical prevalence cannot be calculated reliably from one defining report Suggested: Rare disease; prevalence unknown
Treatment and trials No disease-modifying therapy, genotype-directed treatment, registered CAASDS-specific clinical trial, or validated treatment algorithm was identified Trial/resource search; current Management must be phenotype-directed; absence of identified trials is not proof that none exist in every registry Suggested NCIT: Supportive care; Ophthalmologic examination; Hearing assessment; Genetic counseling
Functional-validation gap No retrieved study directly validated A256S effects on VSX1 protein stability, localization, DNA binding, transcriptional activity, or developmental phenotype Evidence-gap assessment Central limitation for ACMG/AMP interpretation; VSX2 experiments and vsx1/vsx2 double knockouts provide only indirect support (zou2012vsx2controlseye pages 2-4, joaquin2023mutationofvsx pages 1-3) Suggested assay concepts: DNA-binding assay; transcriptional-reporter assay; protein-localization assay; knock-in disease model

Table: This table maps the sparse human and model-organism evidence for CAASDS to suggested ontology concepts. It highlights the major limitations: dependence on one defining human report, uncertain A256S functional evidence, and lack of epidemiologic or therapeutic studies.

Evidence-quality framework

  • Human clinical evidence: one defining report/pedigree, PMID 15051220; no independently replicated CAASDS series was retrieved.
  • Database evidence: MONDO/Open Targets, EVA/ClinVar-linked record RCV000005562, and a Genomics England “amber” monoallelic annotation. These are not independent patient cohorts. The EVA entry is a missense record with “no assertion criteria provided.” (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)
  • Model evidence: mouse VSX1 studies and a 2023 zebrafish vsx1/vsx2 double knockout support retinal bipolar-cell biology, but do not validate human A256S.
  • Inference: CVC-domain dysfunction plausibly affects DNA binding, but direct experimental evidence retrieved for this principle concerns mainly VSX2, not VSX1 A256S. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)

Because the original article’s full text/abstract was not retrievable through the supplied literature tools, exact patient counts, patient-level measurements, segregation details, and verbatim quotations from PMID 15051220 cannot be certified here. The report therefore avoids inventing frequencies or measurements.

1. Disease information

Definition and identifiers

CAASDS is a proposed congenital multisystem developmental disorder combining craniofacial dysmorphism, anterior ocular abnormalities—particularly corneal endothelial change—and neuro-sensory physiological abnormalities. Its defining publication title is itself clinically descriptive: “VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.” (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6)

Identifier/resource Entry or status
OMIM 614195
MONDO MONDO:0013618
Gene VSX1, visual system homeobox 1; former symbol/name RINX
Ensembl gene ENSG00000100987
ClinVar/EVA-linked condition record RCV000005562
PMID 15051220
Orphanet No specific CAASDS identifier established in retrieved evidence
ICD-10/ICD-11 No syndrome-specific code identified; manifestations would require component codes
MeSH No dedicated syndrome heading identified

Open Targets currently recognizes MONDO_0013618 and gives VSX1 an association score of 0.5304, based on literature, genetic, variant, and model evidence. This numerical score is a platform evidence-integration score—not penetrance, pathogenic probability, or clinical validity. A much weaker ZNF469 association (0.0516) derives from model evidence and should not be interpreted as a second established CAASDS gene. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

Synonyms: craniofacial anomalies–anterior segment dysgenesis syndrome; CAASDS; VSX1/RINX-associated craniofacial and ocular syndrome. The source information is primarily aggregated disease-level information derived from a small published family/case report, not longitudinal EHR evidence or a registry cohort.

2. Etiology

Causal factor and genetic risk

The proposed cause is a germline, monoallelic VSX1 missense substitution, p.Ala256Ser, in the conserved CVC domain. Database annotations describe a monoallelic autosomal/pseudoautosomal, non-imprinted requirement, consistent with autosomal-dominant inheritance, but the relevant Genomics England assessment is “amber.” (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

The evidence does not establish whether A256S acts through haploinsufficiency, dominant-negative activity, altered DNA-binding specificity, or another gain-of-function mechanism. No retrieved A256S-specific assay demonstrated altered stability, nuclear localization, DNA binding, transcriptional repression, or developmental phenotype. Studies of VSX-family CVC substitutions indicate that the CVC domain can support high-affinity DNA binding, but the detailed experiments were performed with VSX2, and their results cannot simply be assigned to VSX1. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)

Other risk, protective, and gene–environment factors

No reproducible modifier gene, susceptibility locus, protective allele, environmental exposure, toxin, infection, parental-age effect, lifestyle factor, or gene–environment interaction has been reported specifically for CAASDS. Family history would be relevant if dominant inheritance is confirmed, but numerical recurrence risks depend on confirming variant pathogenicity and parental status.

No protective intervention can prevent a constitutional developmental variant from arising. Prenatal avoidance of alcohol, smoking, teratogenic medication, and infection remains general obstetric care, not CAASDS-specific prevention.

3. Phenotypes

The following phenotype list is conservative. Frequencies cannot be estimated from the available evidence.

Manifestation Type, timing, course Suggested HPO annotation Evidence/limitations
Craniofacial anomalies/dysmorphism Congenital physical sign; severity and progression unknown Craniofacial dysmorphism, abnormality of facial morphology Defining human report; exact features and frequencies unavailable (joaquin2023mutationofvsx pages 41-43)
Anterior-segment dysgenesis/corneal endothelial changes Congenital or developmentally determined ophthalmic sign; later progression unknown Anterior segment dysgenesis; abnormal corneal endothelium; corneal abnormality Human ophthalmic finding in defining report (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6)
Empty sella Structural neuroradiologic sign; congenital/developmental interpretation plausible Empty sella Reported in original study; endocrine consequences not established (joaquin2023mutationofvsx pages 41-43)
Abnormal retinal electrophysiology Functional/laboratory abnormality, potentially affecting vision Abnormal electroretinogram; visual impairment Consistent with VSX1 expression in differentiated cone bipolar-cell subsets, but quantitative ERG results unavailable (joaquin2023mutationofvsx pages 1-3)
Abnormal auditory electrophysiology Functional/laboratory abnormality, potentially affecting hearing Abnormal auditory electrophysiology; hearing impairment Described as abnormal auditory bipolar-cell function; thresholds and clinical hearing status unavailable (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6)

VSX1 is expressed later than VSX2 in retinal development and is restricted in mice to subsets of differentiated ON and OFF cone bipolar cells. Therefore, bipolar-cell dysfunction is biologically coherent. It does not, however, explain the craniofacial, corneal, or sellar findings without additional evidence. (joaquin2023mutationofvsx pages 1-3)

No behavioral, psychiatric, metabolic, hematologic, immune, cardiovascular, renal, or gastrointestinal phenotype has been established. There are no CAASDS-specific EQ-5D, SF-36, PROMIS, or other quality-of-life data. Plausible functional effects include reduced visual/hearing performance and burdens from repeated ophthalmic or audiologic care, but these remain unquantified.

4. Genetic and molecular information

Gene

VSX1 encodes a paired-like homeobox transcription factor containing a DNA-binding homeodomain and adjacent conserved CVC domain. VSX1 and VSX2 are paralogs with related regulatory modules and reported recognition of the DNA motif TAATTAGC, but they differ in developmental timing and functional importance. VSX2 is prominent in early retinal progenitors; VSX1 is associated more with later cone bipolar-cell differentiation. (joaquin2023mutationofvsx pages 1-3)

Suggested annotations include DNA-binding transcription-factor activity, sequence-specific DNA binding, regulation of transcription by RNA polymerase II, retinal development, and bipolar-cell differentiation.

Variant interpretation

  • Reported change: p.Ala256Ser (A256S).
  • Class: missense variant.
  • Origin: presumed constitutional/germline in the reported family; no evidence supports a somatic event.
  • Region: conserved CVC domain.
  • Disease record: RCV000005562.
  • Current caution: the retrieved EVA record supplies no assertion criteria, and modern literature notes that pathogenicity of reported VSX1 CVC variants has been uncertain. (zou2012vsx2controlseye pages 2-4, OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

A current laboratory should normalize the variant against the exact MANE Select transcript and genome assembly before reporting an HGVS cDNA coordinate. No cDNA coordinate, rsID, gnomAD frequency, TOPMed frequency, or ancestry-stratified frequency was verified in the retrieved evidence; none should be inferred from “A256S” alone.

Under ACMG/AMP principles, the historical phenotype/segregation report may contribute case-level or segregation evidence, while location in a conserved functional domain may contribute supporting evidence. However, absent verified population rarity, independent affected families, and A256S-specific functional studies, an unqualified “pathogenic” designation is not adequately supported by the evidence retrieved here. Contemporary reassessment could reasonably remain VUS/uncertain, depending on current database and transcript-specific data.

No confirmed modifier genes, CAASDS-specific methylation signature, chromatin disorder, copy-number variant, translocation, inversion, aneuploidy, or mitochondrial defect has been reported.

5. Environmental information

CAASDS is proposed to be genetic. No toxin, radiation exposure, pollution source, occupation, smoking, alcohol use, diet, exercise pattern, medication, bacterial infection, viral infection, fungal infection, or parasite has been implicated. Environmental teratogens can independently produce craniofacial and ocular abnormalities and therefore belong in the differential diagnosis, but they are not established cofactors for VSX1-associated CAASDS.

6. Mechanism and pathophysiology

Ordered causal chain

  1. A germline VSX1 p.Ala256Ser substitution in the CVC domain is proposed to lead to altered VSX1 molecular function. This initiating genotype–function step is inferred, not directly demonstrated for A256S.
  2. Altered CVC/homeodomain cooperation is inferred to lead to abnormal DNA binding or target-gene regulation. VSX2 experiments support the general CVC-domain principle, but are indirect evidence for VSX1. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)
  3. Abnormal transcriptional control in retinal cone bipolar-cell precursors is inferred to lead to impaired terminal differentiation or physiology. Mammalian expression and knockout observations make this branch biologically plausible. (joaquin2023mutationofvsx pages 1-3)
  4. Bipolar-cell dysfunction leads to abnormal retinal signal processing and electroretinographic findings, potentially causing visual impairment.
  5. A parallel auditory developmental branch is proposed to lead to abnormal auditory electrophysiology, but its VSX1-expressing cell population and molecular route were not established in the retrieved evidence.
  6. A separate, poorly defined embryonic craniofacial/anterior-segment branch is proposed to lead to craniofacial dysmorphism, corneal endothelial change, and empty sella. This connection is clinical association rather than a demonstrated developmental pathway.

Cellular and molecular detail

The best-supported VSX1-relevant cell type is the retinal bipolar neuron, particularly cone bipolar-cell subsets. Suggested Cell Ontology concepts are retinal bipolar neuron, ON-bipolar neuron, OFF-bipolar neuron, cone retinal bipolar cell, retinal progenitor cell, photoreceptor cell, and Müller glial cell.

The 2023 zebrafish study supplies the latest functional and molecular-profiling evidence. CRISPR loss of both vsx1 and vsx2 produced severe visual impairment and bipolar-cell depletion; precursors were rerouted toward photoreceptor or Müller-glial fates, yet neural-retina specification persisted and microphthalmia was absent. Its abstract states: “Our observations point to genetic redundancy as an important mechanism sustaining the integrity of the retinal specification network.” (joaquin2023mutationofvsx pages 1-3)

ATAC-seq found 1,564 differentially accessible regions, but only 5% of genes near altered regions were differentially expressed. Among core retinal-network genes tested by qPCR, significant changes were limited to rx2 and lhx2b. Müller-glial markers increased, whereas amacrine-cell differentiation and spinal V2a/V2b interneuron density were largely preserved. These data imply compensatory network robustness rather than a simple linear loss-of-function cascade. (joaquin2023mutationofvsx pages 7-10)

Suggested GO biological-process terms include retinal development, retinal bipolar-cell differentiation, cell-fate specification, nervous-system development, regulation of transcription, chromatin organization, visual perception, and sensory-system development. Suggested GO cellular components include nucleus, chromatin, and transcription-regulator complex. No CAASDS-specific metabolic, lipidomic, proteomic, immune, inflammatory, oxidative-stress, apoptotic, or fibrosis mechanism has been demonstrated.

No human A256S transcriptomic, single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, CRISPR-screen, iPSC, or organoid profile was identified.

7. Anatomical structures affected

Primary reported organs: eye, craniofacial structures, sellar region, and auditory system.

  • Eye: anterior segment and corneal endothelium; functionally, neural retina/retinal bipolar circuitry.
  • Craniofacial complex: exact bones and soft tissues were not retrievable.
  • Sellar region: empty sella; pituitary endocrine dysfunction was not established.
  • Auditory system: physiological abnormality reported, but exact cochlear/brainstem localization is uncertain.

Suggested UBERON concepts are eye, anterior segment of eyeball, cornea, corneal endothelium, retina, inner nuclear layer of retina, pituitary fossa/sella turcica, craniofacial region, inner ear, and auditory system. Suggested subcellular localization is the nucleus, consistent with a homeobox transcription factor. Laterality—unilateral, bilateral, or asymmetric—cannot be assigned reliably from retrieved evidence.

8. Temporal development

The syndrome is best regarded as congenital/developmental, because craniofacial and anterior-segment malformations arise during embryogenesis. Empty sella may likewise reflect developmental anatomy. The ages at detection of retinal and auditory physiological abnormalities are unavailable.

There is no validated stage model, progression rate, remission pattern, or longitudinal natural history. Structural dysgenesis is expected to be stable, whereas corneal endothelial dysfunction, vision, and hearing could change over time; this is a clinical possibility, not documented CAASDS natural history. Embryonic craniofacial and ocular development constitutes the critical biological period, while infancy and childhood are the practical windows for detecting treatable visual or hearing impairment.

9. Inheritance and population

The historical and database framing is monoallelic/autosomal dominant, but penetrance and expressivity cannot be quantified. The platform annotation explicitly permits autosomal or pseudoautosomal monoallelic inheritance and is graded amber. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1)

No evidence establishes age-dependent penetrance, anticipation, germline mosaicism, founder effect, consanguinity contribution, carrier frequency, ethnicity enrichment, geographic clustering, sex ratio, or age distribution. Prevalence and incidence are unknown; “ultra-rare” is descriptive rather than a measured statistic. Database evidence counts must not be counted as separate patients because several records point back to PMID 15051220.

For counseling, a confirmed heterozygous pathogenic variant in an affected parent would conventionally confer a 50% transmission probability per pregnancy, but the probability of the full CAASDS phenotype cannot be estimated without penetrance data. That calculation should not be applied until current variant classification and familial segregation are reviewed.

10. Diagnostics

Clinical evaluation

There are no consensus CAASDS diagnostic criteria. A reasonable evaluation for a suspected patient includes:

  1. Detailed dysmorphology and three-generation pedigree.
  2. Slit-lamp examination, gonioscopy when indicated, corneal pachymetry and endothelial specular microscopy.
  3. Visual acuity/refraction and retinal examination.
  4. Full-field ERG where bipolar-cell dysfunction is suspected.
  5. Formal audiometry plus auditory brainstem response/electrophysiology when indicated.
  6. Pituitary/sellar MRI if clinically justified; endocrine testing driven by symptoms or imaging findings.

These are phenotype-directed applications, not validated CAASDS criteria.

Genetic testing strategy

  • Preferred: a comprehensive anterior-segment dysgenesis/craniofacial-ocular panel or exome/genome sequencing with CNV analysis, because A256S causality is not firmly established and phenocopies are numerous.
  • VSX1 sequencing: appropriate when the phenotype closely resembles the original report, but should include deletion/duplication analysis where technically available.
  • Familial testing: essential for segregation, penetrance assessment, and reclassification.
  • WES/WGS: useful when panel testing is negative or syndromic features extend beyond the reported spectrum.
  • CMA: useful when multiple congenital anomalies suggest a copy-number disorder.
  • Karyotype/FISH: not first-line unless a structural chromosome abnormality is suspected.
  • Mitochondrial and repeat-expansion testing have no established CAASDS indication.

No validated RNA-seq, proteomic, metabolomic, epigenomic, liquid-biopsy, or biochemical biomarker exists.

Differential diagnosis

Important alternatives include other genetically defined anterior-segment dysgenesis disorders involving PAX6, PITX2, FOXC1, CYP1B1, FOXE3, PITX3, and VSX2; Axenfeld–Rieger spectrum; Peters anomaly; posterior polymorphous corneal dystrophy; congenital hereditary endothelial dystrophy; syndromic craniosynostosis/craniofacial disorders; and teratogenic embryopathies. VSX2-associated microphthalmia must not be conflated with VSX1-associated CAASDS: VSX2 has a stronger experimentally demonstrated role in early eye organogenesis. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)

There is no population newborn screen. Cascade testing is appropriate only after a clinically meaningful familial variant has been confirmed. Prenatal or preimplantation testing requires careful counseling about uncertain pathogenicity and penetrance.

11. Outcome and prognosis

No survival curve, mortality rate, life-expectancy estimate, disability-adjusted burden, or standardized quality-of-life result exists. The reported phenotype does not itself establish reduced lifespan. Expected morbidity is primarily sensory and ophthalmic, with possible craniofacial or endocrine implications depending on the individual.

Potential complications include impaired vision from anterior-segment/corneal disease or retinal signal-processing dysfunction, hearing impairment, and amblyopia during childhood. Empty sella warrants clinical attention to pituitary function, but no CAASDS-specific endocrine complication rate is known. Prognostic biomarkers and validated risk models are absent.

Recovery depends on manifestation: congenital structural abnormalities do not biologically “remit,” but refractive, corneal, hearing, endocrine, and developmental consequences may be mitigated. No treatment-response percentages are available.

12. Treatment and real-world implementation

There is no disease-modifying drug, gene therapy, cell therapy, RNA therapy, immunotherapy, or genotype-targeted treatment for CAASDS. No relevant CAASDS-specific interventional trial or NCT identifier was found in the tool search.

Management is multidisciplinary and manifestation-directed:

  • Ophthalmology: refractive correction, amblyopia prevention, low-vision support, corneal and glaucoma surveillance; corneal surgery or transplantation only for standard clinical indications.
  • Audiology/otolaryngology: hearing aids, assistive devices, or cochlear implantation according to measured deficit—not genotype alone.
  • Craniofacial care: surgical, dental, speech, or psychosocial intervention according to anatomy and function.
  • Endocrinology: evaluate and replace pituitary hormones only when deficiency is documented.
  • Genetics: variant reinterpretation, segregation testing, and reproductive counseling.

Suggested NCIt intervention concepts include ophthalmologic examination, electroretinography, audiometry, auditory brainstem response, magnetic-resonance imaging, genetic counseling, molecular genetic testing, corrective lenses, hearing aid, low-vision rehabilitation, and supportive care. No CAASDS-specific pharmacogenomic interaction is known.

13. Prevention

Primary prevention: none for an inherited constitutional variant. Vaccination, diet, or lifestyle change has no demonstrated effect on CAASDS occurrence.

Secondary prevention: early ophthalmic and hearing assessment may prevent avoidable amblyopia, delayed language development, or educational impact. This is extrapolated standard care rather than trial-proven CAASDS prevention.

Tertiary prevention: surveillance and timely management of corneal, visual, auditory, craniofacial, or endocrine complications.

Genetic counseling should discuss the limited gene–disease evidence, uncertain penetrance, reproductive options, prenatal diagnosis, and preimplantation genetic testing. Such testing is technically possible after familial-variant confirmation, but its predictive value is limited if A256S remains a VUS.

14. Other species and natural disease

No naturally occurring veterinary equivalent of human CAASDS, breed predisposition, VBO term, zoonotic transmission, or cross-species infectious susceptibility was identified. The disorder is not transmissible or zoonotic.

Orthologous vsx1 genes occur across vertebrates. Comparative studies support evolutionary conservation of VSX-family homeodomain/CVC architecture and retinal expression, but regulatory weight differs substantially between mammals, zebrafish, and medaka. (joaquin2023mutationofvsx pages 7-10, joaquin2023mutationofvsx pages 1-3)

Suggested taxa for comparative annotation are Homo sapiens (NCBI Taxonomy 9606), Mus musculus (10090), and Danio rerio (7955).

15. Model organisms

Mouse

Vsx1-deficient mouse work supports roles in retinal cone bipolar-cell differentiation and photopic circuitry. Modern summaries indicate that Vsx1 mutation does not substantially disrupt early retinal specification, even on a Vsx2-mutant background, emphasizing that VSX1 and VSX2 are not functionally interchangeable. Abnormal ERGs have been reported in mice and in some human VSX1 contexts. (joaquin2023mutationofvsx pages 1-3)

Strength: mammalian retinal physiology and cell-type relevance.
Limitation: knockout does not reproduce A256S, and retrieved evidence does not establish craniofacial, corneal-endothelial, sellar, or auditory recapitulation.

Zebrafish—latest development

Letelier et al. used CRISPR-Cas9 to generate a vsx1/vsx2 double knockout, assessed with histology, ERG, optokinetic behavior, RNA-seq, qPCR, and ATAC-seq. The abstract reports “severe visual impairment and bipolar cells depletion” with precursors rerouted to photoreceptor or Müller-glial fates, but says “neural retina is properly specified and maintained” and mutants “do not display microphthalmia.” (joaquin2023mutationofvsx pages 1-3, joaquin2023mutationofvsx pages 33-36)

Quantitatively, 1,564 chromatin-accessibility regions changed, yet only 5% of nearby genes changed expression, demonstrating compensatory network robustness. (joaquin2023mutationofvsx pages 7-10)

Strength: recent functional, electrophysiological, cellular, and multi-omic model.
Limitation: simultaneous loss of vsx1 and vsx2 prevents attribution to vsx1 alone; complete knockout differs fundamentally from A256S; no craniofacial/sellar syndrome was modeled.

Needed models

The decisive experiments would be a human VSX1 A256S knock-in in retinal organoids/iPSC-derived bipolar cells and an orthologous animal knock-in, coupled to protein localization, DNA-binding, transcriptional-reporter, single-cell RNA-seq/ATAC-seq, corneal-endothelial differentiation, ERG, auditory electrophysiology, and craniofacial assessment. Such models were not identified.

Overall expert assessment

CAASDS remains a provisional, extremely sparsely documented syndrome. The phenotype is memorable and biologically compatible with a retinal transcription factor in part, but current support is dominated by one 2004 report and derivative database entries. The key unresolved issue is not whether VSX1 participates in retinal bipolar-cell biology—it does—but whether A256S is truly pathogenic and sufficient to produce the full craniofacial–ocular–sellar–auditory syndrome. Modern VSX biology highlights redundancy, species differences, and the danger of transferring VSX2 CVC-domain results directly to VSX1. (joaquin2023mutationofvsx pages 1-3, zou2012vsx2controlseye pages 2-4)

For knowledge-base purposes, the most defensible representation is: VSX1 p.Ala256Ser–associated CAASDS, limited human evidence; monoallelic inheritance proposed; penetrance and mechanism unknown; variant-specific functional validation absent.

Key references

  1. Mintz-Hittner HA et al. “VSX1 (RINX) mutation with craniofacial anomalies, empty sella, corneal endothelial changes, and abnormal retinal and auditory bipolar cells.” Ophthalmology. April 2004;111:828–836. PMID 15051220. https://pubmed.ncbi.nlm.nih.gov/15051220/ (joaquin2023mutationofvsx pages 41-43, nejabat2017vsx1andsod1 pages 6-6)
  2. Letelier J et al. “Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network.” eLife. 2023; preprint DOI/URL retrieved: https://doi.org/10.1101/2022.01.20.477122. (joaquin2023mutationofvsx pages 7-10, joaquin2023mutationofvsx pages 1-3)
  3. Zou C, Levine EM. “Vsx2 Controls Eye Organogenesis and Retinal Progenitor Identity Via Homeodomain and Non-Homeodomain Residues Required for High Affinity DNA Binding.” PLoS Genetics. September 2012. https://doi.org/10.1371/journal.pgen.1002924. This is indirect VSX-family mechanistic evidence, not direct CAASDS validation. (zou2012vsx2controlseye pages 2-4, zou2012vsx2controlseye pages 4-4)
  4. Nejabat M et al. “VSX1 and SOD1 Mutation Screening in Patients with Keratoconus in the South of Iran.” Journal of Ophthalmic & Vision Research. April 2017;12:135–140. https://doi.org/10.4103/jovr.jovr_97_16. This illustrates broader uncertainty and non-replication around VSX1 corneal-disease associations rather than confirming CAASDS. (nejabat2017vsx1andsod1 pages 6-6)

References

  1. (OpenTargets Search: craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1): Open Targets Query (craniofacial anomalies and anterior segment dysgenesis syndrome-VSX1, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  2. (joaquin2023mutationofvsx pages 1-3): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

  3. (joaquin2023mutationofvsx pages 7-10): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

  4. (zou2012vsx2controlseye pages 2-4): Changjiang Zou and Edward M. Levine. Vsx2 controls eye organogenesis and retinal progenitor identity via homeodomain and non-homeodomain residues required for high affinity dna binding. Sep 2012. URL: https://doi.org/10.1371/journal.pgen.1002924, doi:10.1371/journal.pgen.1002924. This article has 85 citations and is from a domain leading peer-reviewed journal.

  5. (joaquin2023mutationofvsx pages 41-43): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

  6. (nejabat2017vsx1andsod1 pages 6-6): M. Nejabat, Payam Naghash, Hassan Dastsooz, S. Mohammadi, M. Alipour, and M. Fardaei. Vsx1 and sod1 mutation screening in patients with keratoconus in the south of iran. Journal of Ophthalmic & Vision Research, 12:135-140, Apr 2017. URL: https://doi.org/10.4103/jovr.jovr_97_16, doi:10.4103/jovr.jovr_97_16. This article has 24 citations and is from a peer-reviewed journal.

  7. (zou2012vsx2controlseye pages 4-4): Changjiang Zou and Edward M. Levine. Vsx2 controls eye organogenesis and retinal progenitor identity via homeodomain and non-homeodomain residues required for high affinity dna binding. Sep 2012. URL: https://doi.org/10.1371/journal.pgen.1002924, doi:10.1371/journal.pgen.1002924. This article has 85 citations and is from a domain leading peer-reviewed journal.

  8. (joaquin2023mutationofvsx pages 33-36): Joaquín Letelier, Lorena Buono, María Almuedo-Castillo, Jingjing Zang, Constanza Mounieres, Sergio González-Díaz, Rocío Polvillo, Estefanía Sanabria-Reinoso, Jorge Corbacho, Ana Sousa-Ortega, Ruth Diez Del Corral, Stephan C F Neuhauss, and Juan R Martínez-Morales. Mutation of vsx genes in zebrafish highlights the robustness of the retinal specification network. eLife, Jan 2023. URL: https://doi.org/10.1101/2022.01.20.477122, doi:10.1101/2022.01.20.477122. This article has 21 citations and is from a domain leading peer-reviewed journal.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 4
Resolved 3
Unresolved (possible confabulation) 1
Unverifiable 0
References weighed for topical relevance 3
On topic 2
Off topic 0

Unresolved references

These identifiers did not resolve to a record and may be fabricated. A lookup that failed for transport reasons is indistinguishable from one that failed because the record does not exist, so spot-check before acting on them:

  • DOI:10.4103/jovr.jovr_97_16 (5 mentions) - Identifier did not resolve to a record

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 1
Resolved 1
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 1
Terms named correctly 0
Terms named as a different term 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0013618 (4 mentions) - the report calls it "if available", "MONDO"; MONDO calls it craniofacial anomalies and anterior segment dysgenesis syndrome

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • MONDO:0013618 - called "if available", "MONDO"